| Objective To investigate the effect of cetuximab combined with FOLFIRI regimen on serum levels of matrix metalloproteinase-9(MMP-9),tissue inhibitor of metalloproteinase-1(TIMP-1) and epithelial adhesin (E-cadherin) in patients with advanced colorectal cancer(CRC). Methods A total of 118 CRC patients who were treated at the Sixth People’s Hospital of Chengdu, Sichuan Province from October 2019 to February 2021 were selected and divided into a FOLFIRI group (FOLFIRI regimen, n=56) and a combination group (cetuximab combined with FOLFIRI regimen, n=62) according to their different medication preferences. The clinical efficacy of two groups of patients was compared, and the levels of tumor markers, serum MMP-9, TIMP-1, and E-cadherin between the two groupswere recorded. Their safety and survival outcomes were analyzed. Results The objective response rate and disease control rate of patients in the combination group were higher than those in the FOLFIRI group(P<0.05);After treatment,the levels of tumor markers [serum carcinoembryonic antigen(CEA),glycan antigen 19-9 (CA19-9)] and serum related factors[MMP-9,TIMP-1,E-cadherin] in the combination group were lower than those in the FOLFIRI group, and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of toxic side effects such as rash and diarrhea between the two groups of patients(P>0.05).There was no statistically significant difference in the cumulative survival rate(OS) and progression free survival rate(PFS) between the two groups of patients in 4 and 8 months(P>0.05).The combined group had higher OS and PFS in 12,16, and 24 months compared to the FOLFIRI group,and the difference was statistically significant(P<0.05). Conclusion The combination therapy of cetuximab and FOLFIRI regimen shows advantages in improving the efficacy of advanced CRC,improving the expression of tumor markers,reducing serum MMP-9,TIMP-1,E-cadherin levels,and improving prognosis with good safety. |
